Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Size, Share & Industry Analysis, By Drug Class (Androgen Receptor Inhibitors, Microtubule Inhibitors, Gonadotropin Releasing Hormone (GnRH) Agonist, Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, and Others), By Route of Administration (Oral and Parenteral), By Therapy (Chemotherapy, Hormonal Therapy, Targeted Therapy, and Immunotherapy), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI112690

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
2. Pipeline Analysis, by Key Players
3. Overview of Alternative Therapies
4. Key Start-ups in the Market
5. New Product Launches, by Key Players
6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
7. Impact of COVID-19 on the Market
Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Germany
  2. U.K.
  3. France
  4. Italy
  5. Spain
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. GCC
  2. South Africa
  3. Rest of Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2024)
2. Company Profiles
  1. Astellas Pharma Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  2. Pfizer Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  3. Johnson & Johnson Services, Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  4. Sanofi
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  5. Ferring Pharmaceuticals Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  7. AbbVie Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  8. AstraZeneca
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  9. Tolmar, Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  10. Dendreon Pharmaceuticals LLC.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  11. Bayer AG
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
2. Pipeline Analysis, by Key Players
3. Overview of Alternative Therapies
4. Key Start-ups in the Market
5. New Product Launches, by Key Players
6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
7. Impact of COVID-19 on the Market
Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Germany
  2. U.K.
  3. France
  4. Italy
  5. Spain
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. GCC
  2. South Africa
  3. Rest of Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2024)
2. Company Profiles
  1. Astellas Pharma Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  2. Pfizer Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  3. Johnson & Johnson Services, Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  4. Sanofi
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  5. Ferring Pharmaceuticals Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  7. AbbVie Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  8. AstraZeneca
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  9. Tolmar, Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  10. Dendreon Pharmaceuticals LLC.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  11. Bayer AG
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)

Read Less

List of Figures

Figure 1: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032

Figure 2: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024 & 2032

Figure 3: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024 & 2032

Figure 4: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024 & 2032

Figure 5: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024 & 2032

Figure 6: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Region, 2024 & 2032

Figure 7: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032

Figure 8: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024

Figure 9: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032

Figure 10: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024

Figure 11: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032

Figure 12: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024

Figure 13: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 14: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024

Figure 15: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country, 2024 & 2032

Figure 16: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country, 2024

Figure 17: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032

Figure 18: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024

Figure 19: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032

Figure 20: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024

Figure 21: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032

Figure 22: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024

Figure 23: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 24: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024

Figure 25: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 26: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024

Figure 27: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032

Figure 28: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024

Figure 29: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032

Figure 30: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024

Figure 31: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032

Figure 32: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024

Figure 33: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion),by Distribution Channel, 2024 & 2032

Figure 34: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024

Figure 35: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 36: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024

Figure 37: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032

Figure 38: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024

Figure 39: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032

Figure 40: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024

Figure 41: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032

Figure 42: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024

Figure 43: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 44: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024

Figure 45: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 46: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024

Figure 47: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032

Figure 48: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024

Figure 49: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032

Figure 50: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024

Figure 51: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032

Figure 52: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024

Figure 53: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 54: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024

Figure 55: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 56: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024

Figure 57: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Share (%), By Company, 2024

List of Tables

Table 1: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 2: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 3: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019–2032

Table 4: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019–2032

Table 5: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Region, 2019-2032

Table 6: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 7: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 8: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019–2032

Table 9: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019–2032

Table 10: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country, 2019-2032

Table 11: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 12: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 13: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019–2032

Table 14: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019–2032

Table 15: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

Table 16: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 17: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 18: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019–2032

Table 19: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019–2032

Table 20: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

Table 21: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 22: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 23: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019–2032

Table 24: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019–2032

Table 25: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

Table 26: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 27: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 28: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2019–2032

Table 29: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2019–2032

Table 30: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032